DOP2013000158A - COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA Y SU USO COMO INHIBIDOR DUAL DE CINASA PI3/mTOR - Google Patents

COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA Y SU USO COMO INHIBIDOR DUAL DE CINASA PI3/mTOR

Info

Publication number
DOP2013000158A
DOP2013000158A DO2013000158A DO2013000158A DOP2013000158A DO P2013000158 A DOP2013000158 A DO P2013000158A DO 2013000158 A DO2013000158 A DO 2013000158A DO 2013000158 A DO2013000158 A DO 2013000158A DO P2013000158 A DOP2013000158 A DO P2013000158A
Authority
DO
Dominican Republic
Prior art keywords
mtor
quinolin
ona
kinase
dual inhibitor
Prior art date
Application number
DO2013000158A
Other languages
English (en)
Spanish (es)
Inventor
Mary Margaret Mader
David Anthony Barda
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2013000158A publication Critical patent/DOP2013000158A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DO2013000158A 2011-01-14 2013-07-01 COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA Y SU USO COMO INHIBIDOR DUAL DE CINASA PI3/mTOR DOP2013000158A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161432958P 2011-01-14 2011-01-14

Publications (1)

Publication Number Publication Date
DOP2013000158A true DOP2013000158A (es) 2013-11-30

Family

ID=45531593

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000158A DOP2013000158A (es) 2011-01-14 2013-07-01 COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA Y SU USO COMO INHIBIDOR DUAL DE CINASA PI3/mTOR

Country Status (39)

Country Link
US (2) US8440829B2 (OSRAM)
EP (1) EP2663564B1 (OSRAM)
JP (1) JP5891247B2 (OSRAM)
KR (1) KR101561360B1 (OSRAM)
CN (1) CN103282364B (OSRAM)
AR (1) AR084551A1 (OSRAM)
AU (1) AU2012205619B2 (OSRAM)
BR (1) BR112013017672A2 (OSRAM)
CA (1) CA2824760C (OSRAM)
CL (1) CL2013002005A1 (OSRAM)
CO (1) CO6731133A2 (OSRAM)
CR (1) CR20130289A (OSRAM)
CY (1) CY1116007T1 (OSRAM)
DK (1) DK2663564T3 (OSRAM)
DO (1) DOP2013000158A (OSRAM)
EA (1) EA022163B1 (OSRAM)
EC (1) ECSP13012764A (OSRAM)
ES (1) ES2531891T3 (OSRAM)
GT (1) GT201300180A (OSRAM)
HR (1) HRP20150135T1 (OSRAM)
HU (1) HUE024426T2 (OSRAM)
IL (1) IL227165A (OSRAM)
JO (1) JO3003B1 (OSRAM)
ME (1) ME02019B (OSRAM)
MX (1) MX2013008185A (OSRAM)
MY (1) MY164705A (OSRAM)
PE (1) PE20140864A1 (OSRAM)
PH (1) PH12013501493A1 (OSRAM)
PL (1) PL2663564T3 (OSRAM)
PT (1) PT2663564E (OSRAM)
RS (1) RS53828B1 (OSRAM)
SG (1) SG191744A1 (OSRAM)
SI (1) SI2663564T1 (OSRAM)
SV (1) SV2013004496A (OSRAM)
TN (1) TN2013000237A1 (OSRAM)
TW (1) TWI518086B (OSRAM)
UA (1) UA109921C2 (OSRAM)
WO (1) WO2012097039A1 (OSRAM)
ZA (1) ZA201304757B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2015073804A2 (en) * 2013-11-15 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of blocking transmission of malarial parasite
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TW201703769A (zh) 2015-05-08 2017-02-01 美國禮來大藥廠 用於癌症的組合療法
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
SG11201803903YA (en) * 2015-12-15 2018-06-28 Lilly Co Eli Combination therapy for cancer
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
ES2881801T3 (es) 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
WO2017180385A1 (en) * 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
CA3025024A1 (en) 2016-05-20 2017-11-23 Eli Lilly And Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018063873A1 (en) 2016-09-27 2018-04-05 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
IL279329B2 (en) 2018-06-15 2025-01-01 Navitor Pharm Inc Rapamycin analogs and their uses
WO2020081329A1 (en) * 2018-10-18 2020-04-23 Camp4 Therapeutics Corporation Methods and compositions for modulating pcsk9 and angptl3 expression
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス， インコーポレイテッド ラパマイシン類似体及びその使用
CA3184212C (en) * 2020-09-21 2024-11-05 Wei Zhong 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO[4,5-C]QUINOLEIN-2-ONE SUBSTITUTE COMPOUNDS WITH THE ABILITY TO CROSS THE BLOOD-BRAIN BARRIER
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
AU2022421244A1 (en) 2021-12-22 2024-07-11 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
BRPI0416801A (pt) 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
US8158794B2 (en) * 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ES2429170T3 (es) 2005-11-04 2013-11-13 3M Innovative Properties Company 1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
JP2012528829A (ja) 2009-06-04 2012-11-15 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物
WO2010139731A1 (en) 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
JP2012532187A (ja) * 2009-06-30 2012-12-13 ピラマル・ライフ・サイエンシーズ・リミテッド イミダゾ［４，５−ｃ］キノリン誘導体ならびに腫瘍および／または炎症の治療におけるそれらの使用
BR112013013837A2 (pt) * 2010-12-06 2016-09-13 Piramal Entpr Ltd derivados de substituição de imidazoquinolina
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Also Published As

Publication number Publication date
ME02019B (me) 2015-05-20
US20130237562A1 (en) 2013-09-12
ES2531891T3 (es) 2015-03-20
CN103282364B (zh) 2015-06-17
SV2013004496A (es) 2017-11-07
RS53828B1 (sr) 2015-06-30
EA022163B1 (ru) 2015-11-30
KR20130116302A (ko) 2013-10-23
TN2013000237A1 (en) 2014-11-10
AR084551A1 (es) 2013-05-22
ZA201304757B (en) 2014-12-23
TWI518086B (zh) 2016-01-21
PL2663564T3 (pl) 2015-05-29
IL227165A (en) 2016-06-30
KR101561360B1 (ko) 2015-10-16
AU2012205619A1 (en) 2013-06-27
HRP20150135T1 (xx) 2015-03-13
CA2824760C (en) 2016-03-15
PH12013501493A1 (en) 2021-06-02
WO2012097039A1 (en) 2012-07-19
US8440829B2 (en) 2013-05-14
US20120184577A1 (en) 2012-07-19
EA201390823A1 (ru) 2013-12-30
AU2012205619B2 (en) 2015-05-21
PT2663564E (pt) 2015-02-24
TW201307343A (zh) 2013-02-16
EP2663564B1 (en) 2014-12-17
CN103282364A (zh) 2013-09-04
NZ611541A (en) 2015-02-27
CO6731133A2 (es) 2013-08-15
PE20140864A1 (es) 2014-07-19
EP2663564A1 (en) 2013-11-20
SG191744A1 (en) 2013-08-30
DK2663564T3 (en) 2015-01-12
SI2663564T1 (sl) 2015-01-30
ECSP13012764A (es) 2013-09-30
CA2824760A1 (en) 2012-07-19
HK1188454A1 (en) 2014-05-02
JO3003B1 (ar) 2016-09-05
CL2013002005A1 (es) 2013-12-27
CY1116007T1 (el) 2017-01-25
JP5891247B2 (ja) 2016-03-22
BR112013017672A2 (pt) 2018-09-18
MX2013008185A (es) 2013-08-21
UA109921C2 (uk) 2015-10-26
US8658668B2 (en) 2014-02-25
CR20130289A (es) 2013-10-07
JP2014502638A (ja) 2014-02-03
HUE024426T2 (en) 2016-01-28
GT201300180A (es) 2014-04-08
MY164705A (en) 2018-01-30

Similar Documents

Publication Publication Date Title
ECSP13012764A (es) COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA Y SU USO COMO INHIBIDOR DUAL DE CINASA PI3/mTOR
DOP2014000200A (es) Compuestos inhibidores de raf
UY35115A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
ES2609857T3 (es) 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2H-piran-4-il)-1H-imidazo[4,5-C]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominios
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
CR20120596A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
PE20191655A1 (es) Combinaciones farmaceuticas
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
DOP2011000260A (es) Pirimidinas fusionadas
BR112014029708A2 (pt) composto de pirrolo[2,1-f][1,2,4]triazina, método de preparação de compostos de pirrolo[2,1-f][1,2,4]triazina e uso do composto de pirrolo[2,1-f][1,2,4]triazina
BR112014029705A2 (pt) composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
ECSP13012994A (es) COMBINACIÓN DE UN INHIBIDOR DE CINASA DE FOSFATIDIL-INOSITOL-3 (PI3K) Y UN INHIBIDOR DE mTOR
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
BR112017005324A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina
MY182801A (en) Compound for activating ampk and uses thereof
ECSP13012653A (es) COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO Y SU USO PARA EL TRATAMIENTO DE CÁNCER
MX2015008104A (es) Uso de pidotimod para tratar la psoriasis.
TH149217A (th) สารประกอบอิมิดาโซล[4,5-c]ควินอลิน-2-โอน และการใช้ของมันในรูปตัวยับยั้งคู่สำหรับ Pl3 คิเนส/MTOR